drugset / Trial / NCT06930703
Cannabidiol in Sickle Cell Disease
RandomizedParallel-groupQuadruple-blindOther
Summary
Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.
Timeline
- Start
- 2025-04-03
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cannabidiol | Other / unclassified | 200 mg | Oral |
| Comparator | Cannabidiol | Other / unclassified | 400 mg | Oral |
| Comparator | Cannabidiol | Other / unclassified | 600 mg | Oral |